Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.
Twinrix Paediatric is indicated for use in non immune infants, children and adolescents from 1 year up to and including 15 years who are at risk of both hepatitis A and hepatitis B infection.
Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication. The use of Cervarix should be in accordance with official recommendations.
CSL Vifor announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III 1 to improve exercise capacity
Takeda announced that the FDA has approved the supplemental New Drug Application (sNDA) for Iclusig (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
Shire plc has announced the positive response from the European Decentralised Procedure (DCP) for Elvanse Adult in the three European...
The FDA has accepted a new drug application (NDA) seeking the approval of ensartinib (X-396) for the treatment of adult patients with metastatic ALK-positive non–small cell lung cancer (NSCLC), according to an announcement from Xcovery Holdings
Amgen announced the submission of a Supplemental Biologics License Application (sBLA) to the FDA for Nplate (romiplostim) to include the...
BIAL announced that the medicinal product Ongentys (opicapone) for the treatment of adult Parkinson's disease patients with motor fluctuations was...